Kezar Life Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kezar Life Sciences, Inc.
Kezar’s lead asset zetomipzomib has demonstrated clinical significance in a mid-stage lupus trial just weeks after a disappointment in myositis but more robust data are needed for the first-in-class selective immunoproteasome inhibitor.
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Public Company Edition: Is the IPO bubble getting ready to burst? It's anybody's guess, but biopharma companies are forging ahead, having launched 11 first-time offerings during the past week and a half. Also, Heron leads recent follow-on offerings with a $200m stock sale to fund what may soon be its third commercial product.